Article
A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer.
Cancer research and treatment - 1 Oct 2020
Kim Jwa Hoon, Kim Sun Young, Baek Ji Yeon, Cha Yong Jun, Ahn Joong Bae, Kim Han Sang, Lee Keun-Wook, Kim Ji-Won, Kim Tae-You, Chang Won Jin, Park Joon Oh, Kim Jihun, Kim Jeong Eun, Hong Yong Sang, Kim Yeul Hong, Kim Tae Won
Abstract excerpt
PURPOSE: We evaluated the efficacy and safety of avelumab, an anti-PD-L1 antibody, in patients with metastatic or unresectable colorectal cancer (mCRC) with mismatch repair deficiency (dMMR)/microsatellite instability-high (MSI-H) or POLE mutations. MATERIALS AND METHODS: In this prospective, open-label, multicenter phase II study, 33 patients with mCRC harboring dMMR/MSI-H or POLE mutations after failure of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.